Insider · CIK 0001829630

Vavricka John

Reports to the SEC for 1 company · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001829630

Forms 4 and 5

Insider transactions

21 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-01-31	AVIRAtea Pharmaceuticals, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+42.1K sh	—	—	94,164
2026-01-31	AVIRAtea Pharmaceuticals, Inc.F Tax Payment	Chief Commercial Officer	FTax Payment	−11.6K sh	$4.24	−$49.1K	82,594
2026-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−33.3K sh	—	—	0
2026-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−8,750 sh	—	—	0
2026-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+120K sh	—	—	119,520
2025-01-31	AVIRAtea Pharmaceuticals, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+33.3K sh	—	—	54,848
2025-01-31	AVIRAtea Pharmaceuticals, Inc.A Award	Chief Commercial Officer	AAward	+8,750 sh	—	—	63,598
2025-01-31	AVIRAtea Pharmaceuticals, Inc.F Tax Payment	Chief Commercial Officer	FTax Payment	−11.5K sh	$3.06	−$35.2K	52,081
2025-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−33.3K sh	—	—	33,333
2025-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Commercial Officer	AAward	+8,750 sh	—	—	8,750
2025-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+133K sh	—	—	132,800
2024-02-01	AVIRAtea Pharmaceuticals, Inc.S Sale	Chief Commercial Officer	SSale	−11.8K sh	$3.84	−$45.4K	21,515
2024-01-31	AVIRAtea Pharmaceuticals, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+33.3K sh	—	—	33,334
2024-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−33.3K sh	—	—	66,666
2024-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+133K sh	—	—	132,800
2023-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Commercial Officer	AAward	+100K sh	—	—	100,000
2023-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+140K sh	—	—	140,000
2022-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+135K sh	—	—	135,000
2021-01-29	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+117K sh	—	—	117,300
2020-11-03	AVIRAtea Pharmaceuticals, Inc.C Conversion	Chief Commercial Officer	CConversion	+82.5K sh	—	—	82,508
2020-11-03	AVIRAtea Pharmaceuticals, Inc. · Series B Convertible Preferred StockC Conversion	Chief Commercial Officer	CConversion	−82.5K sh	—	—	0

Recent filings

Accepted (ET)
Feb 34
Vavricka John0001193125-26-036272
SEC(opens sec.gov)
Feb 44
Vavricka John0000950170-25-013852
SEC(opens sec.gov)
Feb 24
Vavricka John0000950170-24-010968
SEC(opens sec.gov)
Feb 24
Vavricka John0000899243-23-003600
SEC(opens sec.gov)
Feb 24
Vavricka John0000899243-22-004186
SEC(opens sec.gov)
Feb 14
Vavricka John0000899243-21-003868
SEC(opens sec.gov)
Nov 34
Vavricka John0000899243-20-030323
SEC(opens sec.gov)

Companies

Atea Pharmaceuticals, Inc.Chief Commercial OfficerAVIR

Address

225 FRANKLIN STREET SUITE 2100

BOSTON, MA, 02110